Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells |
Shin, Miyoung
(Division of Life Sciences, Korea University)
Yang, Eun Gyeong (Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology) Song, Hyun Kyu (Division of Life Sciences, Korea University) Jeon, Hyesung (Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology) |
1 | McClelland RA, Barrow D, Madden TA et al (2001) Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142, 2776-2788 DOI |
2 | Jones HE, Goddard L, Gee JM et al (2004) Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11, 793-814 DOI ScienceOn |
3 | Knowlden JM, Hutcheson IR, Jones HE et al (2003) Elevated levels of epidermal growth factor receptor/ c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144, 1032-1044 DOI ScienceOn |
4 | Jin Q and Esteva FJ (2008) Cross-talk between the ErbB/ HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13, 485-498 DOI |
5 | Chakravarti A, Loeffler JS and Dyson NJ (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62, 200-207 |
6 | Liu B, Fang M, Lu Y, Mendelsohn J and Fan Z (2001) Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 20, 1913-1922 DOI |
7 | Morgillo F, Woo JK, Kim ES, Hong WK and Lee HY (2006) Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66, 10100-10111 DOI ScienceOn |
8 | Sachdev D and Yee D (2006) Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia 11, 27-39 DOI |
9 | Carboni JM, Wittman M, Yang Z et al (2009) BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 8, 3341-3349 DOI |
10 | Haluska P, Carboni JM, TenEyck C et al (2008) HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 7, 2589-2598 DOI ScienceOn |
11 | Fan QW, Cheng CK, Nicolaides TP et al (2007) A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 67, 7960-7965 DOI ScienceOn |
12 | Jones RB, Gordus A, Krall JA and MacBeath G (2006) A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439, 168-174 DOI ScienceOn |
13 | Riedemann J, Takiguchi M, Sohail M and Macaulay VM (2007) The EGF receptor interacts with the type 1 IGF receptor and regulates its stability. Biochem Biophys Res Commun 355, 707-714 DOI ScienceOn |
14 | Ryu JH, Shin M, Kim SA et al (2013) In vivo fluorescence imaging for cancer diagnosis using receptor-targeted epidermal growth factor-based nanoprobe. Biomaterials 34, 9149-9159 DOI ScienceOn |
15 | Yarden Y and Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127-137 DOI ScienceOn |
16 | Rakha EA and Chan S (2011) Metastatic triple-negative breast cancer. Clin Oncol 23, 587-600 DOI ScienceOn |
17 | Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121, 2750-2767 DOI ScienceOn |
18 | Yamasaki F, Zhang D, Bartholomeusz C et al (2007) Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther 6, 2168-2177 DOI ScienceOn |
19 | Gallagher EJ and LeRoith D (2010) The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 21, 610-618 DOI ScienceOn |
20 | Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10, 5367-5374 DOI ScienceOn |
21 | DiGiovanni J, Kiguchi K, Frijhoff A et al (2000) Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci U S A 97, 3455-3460 DOI |
22 | Carboni JM, Lee AV, Hadsell DL et al (2005) Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 65, 3781-3787 DOI ScienceOn |
23 | Lee CT, Park KH, Adachi Y et al (2003) Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther 10, 57-63 DOI ScienceOn |
24 | Pollak M (2008) Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol 8, 384-392 DOI ScienceOn |
25 | Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S and LeRoith D (2010) Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes 59, 686-693 DOI ScienceOn |
26 | Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8, 915-928 DOI ScienceOn |